PT  - JOURNAL ARTICLE
AU  - Valérie Leclair
AU  - Océane Landon-Cardinal
AU  - Rohit Aggarwal
AU  - Nick Bansback
AU  - Craig Campbell
AU  - Brian M. Feldman
AU  - Martin Jarry
AU  - Suzan McNamara
AU  - Barbara White
AU  - Marie Hudson
TI  - Proceedings of the 2019 Canadian Inflammatory Myopathy Study Symposium: Clinical Trial Readiness in Myositis
AID  - 10.3899/jrheum.200480
DP  - 2020 Oct 01
TA  - The Journal of Rheumatology
PG  - 1584--1586
VI  - 47
IP  - 10
4099  - http://www.jrheum.org/content/47/10/1584.short
4100  - http://www.jrheum.org/content/47/10/1584.full
SO  - J Rheumatol2020 Oct 01; 47
AB  - The Canadian Inflammatory Myopathy Study (CIMS) is a multicenter prospective cohort recruiting in 8 centers across Canada. One of the aims of CIMS is to conduct and participate in clinical trials in autoimmune inflammatory myopathies (AIM). Conducting clinical trials in rare diseases such as AIM presents challenges. During this symposium, experts in the field presented different solutions to successfully conduct clinical trials in AIM, including the importance of collaboration and careful trial design, as well as training and mentoring of young investigators.